Use of zidovudine in early HIV infection - human immunodeficiency virus - Tips From Other Journals

Date: March, 1991

Treatment with zidovudine is now recommended for certain persons with early human immunodeficiency virus (HIV) infection. The National Institute of Allergy and Infectious Diseases (NIAID) convened an expert panel to make recommendations regarding which patients should receive therapy with zidovudine.

The panel summarized clinical trials that have shown zidovudine can prolong the time between infection and the onset of symptoms of acquired immunodeficiency syndrome. The panel emphasized the importance of accurate HIV antibody testing for all individuals at risk, while acknowledging that there are many difficulties in making an accurate risk assessment.

Once a person is found to be infected with HIV, CD4 T-lymphocyte counts should be performed periodically to assess the need for zidovudine treatment and the need for prophylaxis against Pneumocystics carinii pneumonia. NIAID guidelines for CD4 testing and zidovudine treatment are summarized in Figures 1 and 2.

Care for the HIV-infected patient should take place within a coordinated system of comprehensive primary care that responds to the patient's social, emotional and medical needs. (American Journal of Medicine, September 1990, vol. 89, p. 335.)

COPYRIGHT 1991 American Academy of Family PhysiciansCOPYRIGHT 2004 Gale Group

© 2006,, All Rights Reserved.